Summary To determine the specificity of neuroendocrine protein gene product (PGP9.5) gene transcripts for detecting micrometastatic neuroblastoma, we have used a highly sensitive polymerase chain reaction (PCR) technique to evaluate expression of this gene in normal blood and bone marrow. While expression of the tyrosine hydroxylase gene was not detected in any normal sample, low-level PGP9.5 expression was detected in eight out of ten blood and seven of 12 marrow samples. PGP9.5 gene transcripts in normal tissues have the potential to interfere with the detection of micrometastatic neuroblastoma.
Neuroblastoma is the most common solid tumour of young children. Despite intensive combination chemotherapy, survival for advanced stage disease remains poor, with a high proportion of patients suffering bone marrow relapse (Brodeur and Castleberry, 1993) . The early detection of residual neuroblastoma cells in the peripheral blood or bone marrow of such patients offers the potential of predicting subsequent relapse, and would have immediate clinical implications for patient management (Moss and Sanders, 1990) . In addition, the detection of circulating tumour cells in blood or micrometastases in bone marrow before therapy may also provide valuable information for the diagnosis and staging of this disease.
One of the most sensitive methods for detecting small numbers of tumour cells involves the use of reverse transcription-polymerase chain reaction (RT-PCR) to amplify tumour-specific gene transcripts (Datta et al, 1994; Betz et al, 1995; Foss et al, 1995; Ghossein et al, 1995; Mori et al, 1995) . Preliminary studies on neuroblastoma have suggested two possible target genes for this purpose, namely tyrosine hydroxylase (Naito et al, 1991; Burchill et al, 1994 Burchill et al, , 1995 Miyajima et al, 1995) and neuroendocrine protein gene product PGP9.5 (Mattano et al, 1992; Butturini et al, 1996) . Neuroblastoma cells are specifically characterized by secretion of catecholamines, and tyrosine hydroxylase is the first and ratelimiting enzyme in the catecholamine biosynthetic pathway. PGP9.5 is a ubiquitin carboxy-terminal hydrolase the expression of which has been reported to be primarily restricted to cells of neuroectodermal origin (Thompson et al, 1983; Wilson et al, 1988) .
In order to exclude the likelihood of generating falsely positive results when detecting micrometastatic disease by RT-PCR, it is important that the target gene is not expressed in non-neoplastic cells of the tissues being analysed. Low-level target gene expression by normal cells has the potential to interfere with occult disease detection, and there have been a number of recent reports indicating that particular target genes previously believed to be tumour specific are in fact expressed in normal tissues. For example, Krismann et al (1995) have recently reported a significant number of false-positive results for RT-PCR analysis of cytokeratin 19 mRNA expression in samples of normal peripheral blood, although this gene has been proposed for detection of occult breast and prostate cancer metastases (Wood et al, 1993 Datta et al, 1994 . Likewise, although prostate-specific antigen mRNA and MUC1 mRNA have been used for PCR detection of prostate and breast micrometastases, respectively (Noguchi et al, 1994; Ghossein et al, 1995) , recent reports have demonstrated expression of prostatespecific antigen in cells of non-prostate origin (Smith et al, 1995) , and MUCI expression in non-neoplastic lymph nodes (Hoon et al, 1995) . In view of these findings, we have employed a highly sensitive 'nested' RT-PCR assay in order to evaluate the expression of tyrosine hydroxylase and PGP9.5 in a range of normal blood and bone marrow samples. The results showed PGP9.5 transcripts present at low but clearly detectable levels in both normal blood and marrow specimens, while tyrosine hydroxylase expression was undetectable in all cases. These findings suggest caution should be used in employing PGP9.5 for micrometastatic disease detection.
MATERIALS AND METHODS Cell lines and tissue samples
The neuroblastoma cell line, BE(2)-C, generously supplied by Dr J Biedler (Memorial Sloan-Kettering Cancer Center, NY, USA), was maintained as a monolayer culture at 37°C in RPMI-1640 medium supplemented with L-glutamine (2 mM) and 10% fetal calf serum. Samples of normal blood were obtained from healthy volunteers. Samples of normal bone marrow were obtained either from healthy bone marrow donors or from patients presenting with non-malignant disease.
RT-PCR
Total cellular RNA was isolated from tissues and cultured cells using the method of Chomczynski and Sacchi (1987) and cDNA was reverse transcribed using Moloney murine leukaemia virus reverse transcriptase from 2-gg aliquots using random hexanucleotide primers, essentially as described by Noonan et al, (1990) . Approximately one-fifth of this cDNA mixture was subjected to a 
RESULTS
In order to determine the specificity of tyrosine hydroxylase and PGP9.5 transcripts for neuroblastoma, expression of these target genes was evaluated in a panel of ten normal peripheral blood and 12 normal bone marrow samples using highly sensitive nested PCR analysis. Expression of neither the tyrosine hydroxylase nor PGP9.5 genes was detectable in these normal samples after a single round of PCR (data not shown). The results obtained with the peripheral blood samples following the second round of PCR are shown in Figure IA . Although expression of tyrosine hydroxylase was clearly detectable in the BE(2)-C neuroblastoma cells (lane 1), no expression of this gene was detectable in any of the normal blood samples (lanes 2-11). In contrast, expression of PGP9.5 was clearly detectable, not only in BE(2)-C cells, but also in eight of the ten normal blood samples. Analysis by nested PCR of the target genes in 12 normal bone marrow samples confirmed the high specificity of tyrosine hydroxylase gene expression ( Figure 1B) . Following the second round of PCR, expression of this gene was present in the positive control BE(2)-C cDNA (lane 1) but not in any of the normal marrow samples (lanes 2-13). PGP9.5, however, was found to be expressed in seven of 12 normal bone marrow samples, confirming the non-specific pattern of expression of this gene observed with the peripheral blood samples. For all these samples, the presence of intact cDNA was confirmed by PCR amplification of the control GAPDH gene sequence.
DISCUSSION
A number of preliminary studies have indicated that PCR-based analysis of neuroblastoma-associated gene transcripts might be useful in improving the detection of micrometastatic disease either British Journal of Cancer (1997) 75 (12), [1779] [1780] [1781] Neuroblastoma-specific gene expression 1781 at diagnosis or following therapy (Naito et al, 1991; Burchill et al, 1994 Burchill et al, , 1995 Miyajima et al, 1995 (Smith et al, 1995; Krismann et al, 1995; Hoon et al, 1995) . Although the detection of PGP9.5 expression in normal tissues could presumably be reduced or eliminated by using only a single round of PCR, or by reducing the number of PCR cycles, such manipulations would, of necessity, reduce the sensitivity with which the target tumour cells could also be detected. Since maximal sensitivity is required to avoid the possibility of biological false-negative results (Smith et al, 1995) , such manipulations are undesirable, and the use of target genes that are not expressed in normal tissues is clearly preferable. Earlier studies have suggested that the increased sensitivity attributable to PCR could be used to detect the expression of otherwise tissue-specific genes in any cell type (Chelly et al, 1989; Sarkar et al, 1989) . Chelly et al (1989) have described this form of gene expression as 'illegitimate' transcription, since the level of expression is very low and unlikely to play any significant biological role. Nevertheless, despite the use of highly sensitive nested PCR, illegitimate transcription of tyrosine hydroxylase expression could not be detected in 22 blood and bone marrow specimens from normal donors, suggesting that the gene is under tight regulatory control. This finding is consistent with tyrosine hydroxylase being the ratelimiting enzyme of the catecholamine biosynthetic pathway. Thus, these findings confirm the suitability of tyrosine hydroxylase gene expression for studies involving the PCR-based detection of micrometastatic neuroblastoma in blood and bone marrow. In contrast, positive results obtained following the use of PGP9.5 as the target gene should be interpreted with caution given the frequent expression of this gene in normal cells of haematopoietic origin.
